Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for BL-M12D1 for Injection (ADC) for the Treatment of Hematological Malignancies

Sep 28, 2026 · Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Filed with SSE · Stock code 688506 · Sep 28, 2026

Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for BL-M12D1 for Injection (ADC) for the Treatment of Hematological Malignancies

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

View original source (Shanghai Stock Exchange)Company analysis

Earlier from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Early Return of Raised Funds Used to Temporarily Supplement Working CapitalSep 24
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Triggering of Milestone Payment Conditions under the Global Strategic Collaboration Agreement between Its Wholly-owned Subsidiary SystImmune and Bristol Myers Squibb for Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren)Sep 22
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Joint Investment with Related PartiesSep 18
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for Neoadjuvant Therapy in HER2-positive Breast CancerSep 14

All Sichuan Biokin Pharmaceutical Co., Ltd. Class A news releases